RBC Capital maintains Nuvation Bio at Outperform, lowers price target to $17 from $20

RBC Capital maintained Nuvation Bio at Outperform and lowered its price target to $17 from $20, a 15.0% decrease.

The price target implies an upside of 259.4% from the Nov 4 close of $4.73.

Explore more price target data and ratings for Nuvation Bio on the Forecasts tab, and track all previous and future analyst recommendations in the dedicated News Flow.